Kukje Pharma Co., Ltd. (KRX:002720)
South Korea · Delayed Price · Currency is KRW 4,550.00
+60.00 (1.34%)
Feb 19, 2026, 9:09 AM KST
Kukje Pharma Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 173,795 | 156,463 | 135,373 | 126,583 | 119,746 | 130,395 |
Other Revenue | -0 | -0 | -0 | -0 | -0 | - |
| 173,795 | 156,463 | 135,373 | 126,583 | 119,746 | 130,395 | |
Revenue Growth (YoY) | 15.77% | 15.58% | 6.94% | 5.71% | -8.17% | 17.34% |
Cost of Revenue | 79,976 | 73,968 | 68,148 | 63,329 | 65,275 | 65,590 |
Gross Profit | 93,819 | 82,495 | 67,225 | 63,254 | 54,470 | 64,805 |
Selling, General & Admin | 81,997 | 72,895 | 66,699 | 56,119 | 53,538 | 49,234 |
Research & Development | 2,447 | 1,811 | 2,646 | 1,967 | 2,772 | 3,037 |
Amortization of Goodwill & Intangibles | 14.78 | 19.91 | 199.15 | 233.84 | 227.46 | 217.25 |
Operating Expenses | 85,148 | 75,793 | 69,214 | 57,982 | 56,146 | 58,763 |
Operating Income | 8,670 | 6,702 | -1,989 | 5,273 | -1,676 | 6,041 |
Interest Expense | -961.26 | -1,206 | -1,440 | -1,000 | -696.43 | -650.13 |
Interest & Investment Income | 462.39 | 428.67 | 394.02 | 230.88 | 114.3 | 139.41 |
Earnings From Equity Investments | - | - | - | 23.21 | -72.91 | -13.43 |
Currency Exchange Gain (Loss) | 260.83 | 303.91 | 163.51 | 450.12 | 589.96 | -688.75 |
Other Non Operating Income (Expenses) | 694.07 | 492.72 | -2,254 | 270.73 | 627.72 | 340.29 |
EBT Excluding Unusual Items | 9,126 | 6,721 | -5,126 | 5,247 | -1,113 | 5,169 |
Gain (Loss) on Sale of Investments | 5.47 | 0.59 | 22.11 | - | - | 26.38 |
Gain (Loss) on Sale of Assets | 35.47 | 114.27 | 290.39 | 13.93 | 31.51 | 366.75 |
Asset Writedown | -228.27 | -226.64 | -1,867 | -515.82 | -28.5 | 31.68 |
Pretax Income | 8,939 | 6,609 | -6,681 | 4,745 | -1,110 | 5,594 |
Income Tax Expense | 1,801 | 1,403 | 1,734 | 1,202 | 445.53 | 3,399 |
Earnings From Continuing Operations | 7,138 | 5,206 | -8,415 | 3,543 | -1,556 | 2,195 |
Minority Interest in Earnings | -0.73 | -0.9 | -0.3 | 14.56 | -3.34 | 8.43 |
Net Income | 7,137 | 5,205 | -8,415 | 3,557 | -1,559 | 2,203 |
Net Income to Common | 7,137 | 5,205 | -8,415 | 3,557 | -1,559 | 2,203 |
Net Income Growth | 73.72% | - | - | - | - | - |
Shares Outstanding (Basic) | 20 | 20 | 20 | 20 | 20 | 20 |
Shares Outstanding (Diluted) | 20 | 20 | 20 | 20 | 20 | 20 |
Shares Change (YoY) | 0.22% | 0.53% | -0.03% | -0.03% | -0.03% | -0.00% |
EPS (Basic) | 350.36 | 255.64 | -415.49 | 175.58 | -76.93 | 108.67 |
EPS (Diluted) | 350.36 | 255.64 | -415.49 | 175.58 | -77.14 | 108.67 |
EPS Growth | 73.34% | - | - | - | - | - |
Free Cash Flow | 9,424 | 1,029 | 2,529 | 5,245 | 7,705 | -6,500 |
Free Cash Flow Per Share | 462.63 | 50.53 | 124.88 | 258.88 | 380.18 | -320.63 |
Dividend Per Share | 30.000 | 30.000 | - | - | - | - |
Gross Margin | 53.98% | 52.73% | 49.66% | 49.97% | 45.49% | 49.70% |
Operating Margin | 4.99% | 4.28% | -1.47% | 4.17% | -1.40% | 4.63% |
Profit Margin | 4.11% | 3.33% | -6.22% | 2.81% | -1.30% | 1.69% |
Free Cash Flow Margin | 5.42% | 0.66% | 1.87% | 4.14% | 6.43% | -4.98% |
EBITDA | 11,869 | 9,904 | 2,215 | 9,760 | 2,743 | 9,667 |
EBITDA Margin | 6.83% | 6.33% | 1.64% | 7.71% | 2.29% | 7.41% |
D&A For EBITDA | 3,198 | 3,203 | 4,204 | 4,488 | 4,419 | 3,626 |
EBIT | 8,670 | 6,702 | -1,989 | 5,273 | -1,676 | 6,041 |
EBIT Margin | 4.99% | 4.28% | -1.47% | 4.17% | -1.40% | 4.63% |
Effective Tax Rate | 20.15% | 21.23% | - | 25.34% | - | 60.77% |
Advertising Expenses | - | 3,692 | 6,015 | 7,504 | 7,250 | 6,300 |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.